Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide.

Humans Transplantation, Haploidentical Graft vs Host Disease Retrospective Studies T-Lymphocytes Cyclophosphamide / therapeutic use Hematopoietic Stem Cell Transplantation / methods Transplantation Conditioning / methods

Journal

Bone marrow transplantation

ISSN: 1476-5365

Titre abrégé: Bone Marrow Transplant

Pays: England

ID NLM: 8702459

Informations de publication

Date de publication:
12 2022

Historique:

received: 11 06 2021

accepted: 04 01 2022

revised: 07 12 2021

pubmed: 4 9 2022

medline: 6 12 2022

entrez: 3 9 2022

Statut: ppublish

Résumé

Donor selection may contribute to improve clinical outcomes of T cell-replete haploidentical stem cell transplantation (Haplo-SCT) with post-transplant cyclophosphamide (PT-Cy). Impact of second-degree related donor (SRD) was not fully elucidated in this platform. We retrospectively compared the outcome of patients receiving Haplo-SCT either from a SRD (n = 31) or a first-degree related donor (FRD, n = 957). Median time to neutrophil and platelet recovery did not differ between a SRD and a FRD transplant (p = 0.599 and 0.587). Cumulative incidence of grade II-IV acute graft-versus host disease (GVHD) and moderate-severe chronic GVHD was 13% and 19% after SRD vs 24% (p = 0.126) and 13% (p = 0.395) after FRD transplant. One-year cumulative incidence of non-relapse mortality (NRM) was 19% for SRD and 20% for FRD (p = 0.435) cohort. The 3-year probability of overall survival (OS) and progression-free survival (PFS) was 42% vs 55% (p = 0.273) and 49% vs 35% (p = 0.280) after SRD and FRD transplant, respectively. After propensity score adjustment or matched pair analysis, the outcome of patients receiving Haplo-SCT from a SRD or a FRD did not differ in terms of NRM, OS, PFS, acute and chronic GVHD. Our results suggest that a SRD is a viable option for Haplo-SCT with PT-Cy when a FRD is not available.

Identifiants

DOI: 10.1038/s41409-022-01565-1 PMID: 36057732

pubmed: 36057732

doi: 10.1038/s41409-022-01565-1

pii: 10.1038/s41409-022-01565-1

doi:

Substances chimiques

Cyclophosphamide 8N3DW7272P

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

1758-1764

Informations de copyright

Références

Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641–50.

doi: 10.1016/j.bbmt.2008.03.005

Chang YJ, Huang XJ. Haploidentical bone marrow transplantation without T-cell depletion. Semin Oncol. 2012;39:653–6.

doi: 10.1053/j.seminoncol.2012.09.003 pubmed: 23206842

Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai H-L, Bolanos-Meade J, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transpl. 2010;16:482–9.

doi: 10.1016/j.bbmt.2009.11.011

Ciurea SO, Al Malki MM, Kongtim P, Fuchs EJ, Luznik L, Huang XJ, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensusrecommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transpl. 2020;55:12–24.

doi: 10.1038/s41409-019-0499-z

Canaani J, Savani BN, Labopin M, Huang XJ, Ciceri F, Arcese W, et al. Impact of ABO incompatibility on patient outcome in haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the acute leukemia working party of the EBMT. Haematologica. 2017;102:1066–74.

doi: 10.3324/haematol.2016.160804 pubmed: 28255020 pmcid: 5451338

Canaani J, Savani BN, Labopin M, Huang XJ, Ciceri F, Arcese W, et al. Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. Am J Hematol. 2018;93:246–53.

doi: 10.1002/ajh.24963 pubmed: 29114918

Mariotti J, Raiola AM, Evangelista A, Carella AM, Martino M, Patriarca F, et al. Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. Blood Adv. 2020;4:3900–12.

doi: 10.1182/bloodadvances.2020001620 pubmed: 32813875 pmcid: 7448598

DeZern A, Franklin C, Tsai HL, Imus PH, Cooke KR, Varadhan R, et al. Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv. 2021;5:1360–8.

doi: 10.1182/bloodadvances.2020003922 pubmed: 33661299 pmcid: 7948266

McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolaños-Meade J, Rosner GL. Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation with High-dose post-transplantation cyclophosphamide in older adults. Blood. 2015;125:3024–31.

doi: 10.1182/blood-2015-01-623991 pubmed: 25814532 pmcid: 4424420

Solomon SR, Aubrey MT, Zhang X, Piluso A, Freed BM, Brown S, et al. Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical Variables. Biol Blood Marrow Transpl. 2018;24:789–98.

doi: 10.1016/j.bbmt.2018.01.013

Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Blaise D, et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study. Br J Haematol. 2020;188:745–56.

doi: 10.1111/bjh.16182 pubmed: 31498883

Garnier A, Guillaume T, Peterlin P, Bene MC, Le Bris Y, Dubruille V, et al. Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier. Bone Marrow Transpl. 2017;52:1063–4.

doi: 10.1038/bmt.2017.60

Elmariah H, Kasamon YL, Zahurak M, Macfarlane KW, Tucker N, Rosner GL, et al. Haploidentical bone marrow transplantation with post-transplant cyclophosphamide using non-first-degree related donors. Biol Blood Marrow Transpl. 2018;24:1099–102.

doi: 10.1016/j.bbmt.2018.02.005

Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628–33.

doi: 10.1016/j.bbmt.2009.07.004

Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transpl. 1995;15:825–8.

Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945–56.

doi: 10.1016/j.bbmt.2005.09.004

Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Aroa M, Brunstein CG, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 2015;125:1333–8.

doi: 10.1182/blood-2014-10-609032 pubmed: 25593335 pmcid: 4335084

Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.

doi: 10.1080/01621459.1958.10501452

Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.

doi: 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O pubmed: 10204198

Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–7.

doi: 10.1080/01621459.1999.10474144

Zhang YY, Liu DH, Liu KY, Xu L-P, Chen H, Han W, et al. HLA-haploidentical hematopoietic SCT from collateral related donors without in vitro T-cell depletion for hematological malignancies. Bone Marrow Transpl. 2014;49:496–501.

doi: 10.1038/bmt.2013.223

Mo XD, Zhang YY, Zhang XH, Xu L-P, Wang Y, Yan C-H, et al. The role of collateral related donors in haploidentical hematopoietic stem cell transplantation. Sci Bull. 2018;63:1376–82.

doi: 10.1016/j.scib.2018.08.008

Chang YJ, Luznik L, Fuchs EJ, Huang XJ. How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation? J Hematol Oncol. 2016;9:35.

doi: 10.1186/s13045-016-0265-2 pubmed: 27071449 pmcid: 4830035

McCurdy SR, Luznik L. How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. Hematol Am Soc Hematol Educ Program. 2019;2019:513–21.

doi: 10.1182/hematology.2019001323

McCurdy SR, Zhang MJ, St Martin A, Al Malki MM, Bashey A, Gaballa S, et al. Effect of donor charac- teristics on haploidentical transplantation with post-transplantation cy- clophosphamide. Blood Adv. 2018;2:299–307.

doi: 10.1182/bloodadvances.2017014829 pubmed: 29440002 pmcid: 5812334